Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

S.Korea's Celltrion surges; co's Remicade copy to be tested for COVID-19 treatment

** Drugmaker Celltrion Inc's  068270.KS  shares rise as much
as 11.5% to their highest since March 2018
    ** Britain's University of Birmingham will test Remsima, the
biosimilar version of the anti-inflammatory drug Remicade
developed by Celltrion, it said on Wednesday, to see if the drug
could reduce the severity of COVID-19.  urn:newsml:reuters.com:*:nL8N2DN230
    ** Celltrion's distribution affiliate, Celltrion Healthcare
 091990.KQ  saw shares rise as much as 12% 
    ** The benchmark KOSPI market  .KS11  was trading down 0.8%
    

 (Reporting by Joyce Lee)
 ((jungyoon.lee@tr.com; +82 2 6936 1467;))

Recent news on Celltrion Healthcare Co

See all news